NDA 020607 · Pfizer
Arthrotec
Diclofenac Sodium, Misoprostol · Oral · Prostaglandin E1 Analog
Last checked: Nov 19, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Dec 24, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
492
123 Phase 3, 29 recruiting
FAERS reports
6,640
5,019 serious, 306 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF UTERINE RUPTURE, ABORTION, PREMATURE BIRTH, BIRTH DEFECTS; SERIOUS CARDIOVASCULAR EVENTS; AND SERIOUS GASTROINTESTINAL EVENTS Uterine Rupture, Abortion, Premature Birth, and Birth Defects • Administration of misoprostol, a component of diclofenac sodium/misoprostol, to pregnant women can cause uterine rupture, abortion, premature birth, or birth defects. Uterine rupture has occurred when misoprostol was administered in pregnant women to induce labor or an abortion [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) ] . • Diclofenac sodium/misoprostol is contraindicated in pregnancy [see Contraindications (4) ] and not recommended in women of childbearing potential. Patients must be advised of the abortifacient property and warned not to give the drug to others [see Warnings and Precautions (5.1) ] . • If diclofenac sodium/misoprostol is prescribed,...
What it is approved for
From the label in effect Aug 31, 2026.
Diclofenac sodium/misoprostol is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. For a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications [see Warnings and Precautions (5.3) ] . Diclofenac sodium/misoprostol is a combination of diclofenac sodium, a non‑steroidal anti‑inflammatory drug, and misoprostol, a prostaglandin-1 (PGE1) analog, indicated for the treatment of signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing NSAID‑induced gastric and duodenal ulcers and their complications. ( 1 )
Mechanism: Diclofenac sodium/misoprostol is a combination product containing diclofenac sodium, an NSAID with analgesic, anti-inflammatory and antipyretic properties, and misoprostol, a GI mucosal protective prostaglandin-1 (PGE1) analog. Diclofenac The mechanism of action of diclofenac, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin (PG) synthesis in vitro. Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 24, 1997 Original approval · Type 4 - New Combination Review
2 products under this application
- ARTHROTEC · DICLOFENAC SODIUM 75MG; MISOPROSTOL 0.2MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
- ARTHROTEC · DICLOFENAC SODIUM 50MG; MISOPROSTOL 0.2MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Diclofenac" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Safety of an Investigational Drug (Etoricoxib) in Patients With Osteoarthritis (OA) or Rheumatoid Arthritis (RA)(0663-066)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00250445 · 23,498 participants · Start Jan 2003 · Primary completion May 2006
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Rheumatoid Arthritis,Osteoarthritis
- The Standard Care Versus Celecoxib Outcome TrialPivotal-lookingCompleted
University of DundeeAcademic, hospital or other
NCT00447759 · 7,297 participants · Start Jun 2007 · Primary completion Aug 2015
Drug: Celecoxib; Diclofenac · For: Osteoarthritis; Rheumatoid Arthritis
Sites: Odense, Denmark; Zeist, Netherlands; Aberdeen, United Kingdom · 10 sites in all
- Investigational Drug Versus an Approved Drug in Patients With Osteoarthritis (0663-061)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092703 · 6,000 participants · Start Jun 27, 2002 · Primary completion Nov 1, 2003
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Osteoarthritis
- Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With ArthritisPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00141102 · 4,484 participants · Start Oct 2005 · Primary completion May 2009
Drug: Celecoxib; Diclofenac + Omeprazole · For: Osteoarthritis; Arthritis, Rheumatoid
Sites: Genk, Belgium; Ghent, Belgium; Hasselt, Belgium · 194 sites in all
- Investigational Drug Versus an Approved Drug in Patients With Rheumatoid Arthritis (0663-072)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092742 · 4,086 participants · Start Feb 2003 · Primary completion Dec 2005
Drug: MK0663, etoricoxib; Comparator: Diclofenac sodium · For: Rheumatoid Arthritis
- Indomethacin vs Diclofenac for Preventing PEPPivotal-lookingRecruiting
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT07071441 · 4,050 participants (planned) · Start Jun 1, 2025 · Primary completion Dec 31, 2026
Drug: Indomethacin 100 MG; Diclofenac 100mg · For: ERCP; Pancreatitis; Non-steroidal Anti-inflammatory (NSAID) and 2 more
Sites: Beijing, China; Chongqing, China; Xiamen, China · 20 sites in all
- Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or KneePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02528188 · 3,021 participants · Start Jul 21, 2015 · Primary completion Oct 5, 2018
Drug: NSAID; Tanezumab 2.5 mg and 1 more · For: Chronic Pain; Osteoarthritis, Hip; Osteoarthritis, Knee
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 507 sites in all
- Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or HipPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03304379 · 1,650 participants · Start Oct 26, 2017 · Primary completion Dec 13, 2019
Drug: Fasinumab; Matching placebo · For: Osteoarthritis, Knee; Osteoarthritis, Hip
Sites: Anniston, Alabama; Mobile, Alabama; Chandler, Arizona · 71 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,203
- pain900
- arthralgia777
- rheumatoid arthritis685
- nausea634
- fatigue557
- drug hypersensitivity520
- diarrhoea518
- malaise450
- headache414
- dizziness411
- pain in extremity384
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 191 |
| 2005 | 282 |
| 2006 | 249 |
| 2007 | 247 |
| 2008 | 205 |
| 2009 | 231 |
| 2010 | 381 |
| 2011 | 290 |
| 2012 | 416 |
| 2013 | 340 |
| 2014 | 276 |
| 2015 | 371 |
| 2016 | 401 |
| 2017 | 366 |
| 2018 | 443 |
| 2019 | 498 |
| 2020 | 615 |
| 2021 | 248 |
| 2022 | 222 |
| 2023 | 131 |
| 2024 | 128 |
| 2025 | 74 |
| 2026 | 35 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis.
da Costa BR, Pereira TV, Saadat P, et al. · BMJ 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.
Santhosh A, Sharma A, Bakhshi S, et al. · J Clin Oncol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Diclofenac.
Ogle C · Conn Med 1989 · Clinical Trial, Randomized Controlled Trial
- Topical NSAIDs for acute musculoskeletal pain in adults.
Derry S, Moore RA, Gaskell H, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Rofecoxib for osteoarthritis.
Garner SE, Fidan DD, Frankish R, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Efficacy and safety of simple analgesics for acute treatment of episodic tension-type headache in adults: a network meta-analysis.
Xie R, Li J, Jing Y, et al. · Ann Med 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.